Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
about
Current and emerging therapies in unresectable and recurrent gastric cancerAdvanced gastric cancer: Current treatment landscape and future perspectivesChemotherapy in Elderly Patients with Gastric CancerClinical utility of ramucirumab in advanced gastric cancerMolecular classification of gastric cancer: Towards a pathway-driven targeted therapyCerebral ischemic events in patients with pancreatic cancer: A retrospective cohort study of 17 patients and a literature reviewPositioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinomamRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancerEffect of oxaliplatin combined with polyenephosphatidylcholine on the proliferation of human gastric cancer SGC-7901 cellsSrc mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma modelsImmunohistochemical profile for unknown primary adenocarcinoma.Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study.Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis.A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.Effectiveness and safe use of modified FOLFOX-6 for metastatic gastric cancer with signet ring cell components complicated by disseminated intravascular coagulation and diffuse bone marrow carcinomatosis.The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer.Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer.Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma.Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: A meta-analysis of randomized controlled trials.Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer.VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Eight-year survival after advanced gastric cancer treated with S-1 followed by surgery.Clinical significance of POU5F1P1 rs10505477 polymorphism in Chinese gastric cancer patients receving cisplatin-based chemotherapy after surgical resection.Decline of serum CA724 as a probable predictive factor for tumor response during chemotherapy of advanced gastric carcinomaTargeted therapies for gastric cancer: current status.Recent advances in chemotherapy for advanced gastric cancerStandard First-Line Chemotherapy for Metastatic Gastric Cancer in Japan Has Met the Global Standard: Evidence From Recent Phase III Trials.The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancerNeoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954.Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
P2860
Q26745453-0AC3CA17-8F4C-40CE-BE34-9E6C5DF5338EQ26764934-64ACB73B-D962-4B9A-B9FC-60D8EE371133Q26771424-D4EEAC8A-8FDD-48C7-9113-63433F0A633AQ26785665-32A85B28-92BC-4733-B775-451F5827D2B0Q26798420-74276EF5-8F07-4E26-9F23-5E73F02FE9CFQ27314885-B103BDB1-C7B9-4F1E-B871-0BB676B7C0C6Q28079750-B929CADF-E653-45F5-A5A4-EC2CC8B1F3D8Q28246258-40AD579D-9A6B-4DB2-BC5A-A9923B2DEB68Q28468621-F754E73F-F14A-464F-82DD-8437DEEFEDC8Q28544422-F7ECE660-4925-4507-8095-5EA41F850E24Q31047832-C780BC63-488A-4064-9B42-37862A291F11Q33383287-0098193C-94F4-4C6D-9BE0-FDA222E32A39Q33386875-6DFC459D-66EF-4441-A0C0-6FB095B52907Q33389036-E79A0BFA-E0F9-41DF-BBA4-D8970D73C093Q33391384-DA8A78C6-A411-4651-89EB-FC5937AFA525Q33396506-F089753C-FE75-4B24-9FB5-382B577DA18FQ33399154-104E1A7C-AB57-427B-8C9A-3530B0F402CBQ33399530-235E23D0-34DD-4F6A-A3B9-CE98E020CDA0Q33400238-FFA96912-8246-4060-9678-A609B135134CQ33402388-F1E87E70-913C-4AFA-A87D-DFD4F26DF33BQ33405235-004F13E7-4254-40A8-A823-1CAA9B74169FQ33413350-CCF6734C-9389-4F4E-95EC-9A72F34F481EQ33416115-432B19AE-E161-46D0-A987-575CAC2249E1Q33420157-2472425A-460B-4AA4-A259-C87FD9357A9AQ33425150-662293D2-7A61-4B20-BADF-C0ECA59D2A5AQ33432145-52844A83-604E-4B1A-BA67-67C9FD0A02A1Q33658636-C0FCD5E6-BC64-488F-A4F5-E12DB4E0FAECQ33729150-75DB3CF8-242C-4689-9DA7-5B59787B640BQ33889468-2EBC412E-0A87-473A-9BBC-82F95DDA70B7Q33903658-811C549D-C6E5-49C0-ACBF-3DA5348442FDQ34072513-CF0060D8-C7E6-4811-BFD0-2A14E3EC0BB5Q34130176-CF9BD3EF-115C-4839-94A7-1C361B8EB148Q34205672-8D8519EC-E4D8-4036-BDE4-39178A450626Q34389753-A3291C88-9D08-48E8-AB96-1C5E3E5B38BCQ34395983-41C660E5-4BFE-47F6-B3CA-EE673ABB8508Q34478504-1DC501B9-CA6F-4302-8F30-6BB628EACBD5Q34488692-367739E1-95F3-4552-9544-B0F1FE2D4998Q34594956-251BCD33-E459-47E2-8928-D40D4384A15DQ34608899-6769D98F-127D-4252-B775-2D248315800FQ34609932-74175106-EFDD-4370-8561-BC665AFF3934
P2860
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Phase III trial in metastatic ...... haft Internistische Onkologie.
@en
Phase III trial in metastatic ...... haft Internistische Onkologie.
@nl
type
label
Phase III trial in metastatic ...... haft Internistische Onkologie.
@en
Phase III trial in metastatic ...... haft Internistische Onkologie.
@nl
prefLabel
Phase III trial in metastatic ...... haft Internistische Onkologie.
@en
Phase III trial in metastatic ...... haft Internistische Onkologie.
@nl
P2093
P356
P1476
Phase III trial in metastatic ...... haft Internistische Onkologie.
@en
P2093
Akin Atmaca
Alexander Knuth
Arbeitsgemeinschaft Internistische Onkologie
Carsten Bokemeyer
Claudia Pauligk
Elke Jäger
Gerhard Wilhelm
Gernot Seipelt
Gunter Schuch
Hans Günter Derigs
P304
P356
10.1200/JCO.2007.13.9378
P407
P577
2008-03-01T00:00:00Z